C4.4A as a candidate marker in the diagnosis of colorectal cancer by Paret, C et al.
C4.4A as a candidate marker in the diagnosis of colorectal cancer
C Paret
1, D Hildebrand
1, J Weitz
2, A Kopp-Schneider
3, A Kuhn
4, A Beer
1, R Hautmann
5 a n dMZ o ¨ller*,1,6
1Department of Tumour Progression and Immune Defence, German Cancer Research Centre, Heidelberg, Germany;
2Department of Surgery, University
of Heidelberg, Heidelberg, Germany;
3Department of Biostatistics, German Cancer Research Centre, Heidelberg, Germany;
4Department of
Immunogenetics, German Cancer Research Centre, Heidelberg, Germany;
5Department of Urology, University of Ulm, Ulm, Germany;
6Department of
Applied Genetics, University of Karlsruhe, Karlsruhe, Germany
C4.4A is a member of the Ly-6 family with restricted expression in non-transformed tissues. C4.4A expression in human cancer has
rarely been evaluated. Thus, it became important to explore C4.4A protein expression in human tumour tissue to obtain an estimate
on the frequency of expression and the correlation with tumour progression, the study focusing on colorectal cancer. The analysis of
C4.4A in human tumour lines by western blot and immunoprecipitation using polyclonal rabbit antibodies that recognize different
C4.4A epitopes revealed C4.4A oligomer and heavily glycosylated C4.4A isoform expression that, in some instances, inhibited
antibody binding and interaction with the C4.4A ligand galectin-3. In addition, tumour cell lines released C4.4A by vesicle shedding
and proteolytic cleavage. C4.4A was expressed in over 80% of primary colorectal cancer and liver metastasis with negligible
expression in adjacent colonic mucosa, inflamed colonic tissue and liver. This compares well with EpCAM and CO-029 expression in
over 90% of colorectal cancer. C4.4A expression was only observed in about 50% of pancreatic cancer and renal cell carcinoma. By
de novo expression in colonic cancer tissue, we consider C4.4A as a candidate diagnostic marker in colorectal cancer, which possibly
can be detected in body fluids.
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C4.4A is a highly glycosylated glycosylphosphatidylinositol (GPI)-
anchored protein with 30% homology to the urokinase receptor
(uPAR) (Ro ¨sel et al, 1998). C4.4A, also described as Ly6/PLAUR
domain containing 3, and uPAR belong to the Ly-6 family,
characterised by repetitive cysteine residues which allow a typical
‘three finger’ folding via disulphide bridges (Tsetlin, 1999). While
uPAR has three cysteine containing domains, C4.4A has two and
the third domain is devoid of cysteines (Ro ¨sel et al, 1998). Most
other members of the Ly-6 family have only one domain (Ploug
and Ellis, 1994).
The C4.4A protein was first identified in a highly metastasizing
rat pancreatic adenocarcinoma line (Matzku et al, 1989). In the rat,
C4.4A (rC4.4A) is strongly upregulated during implantation of the
blastocyst and is highly expressed in the placenta. In the adult,
expression is restricted mostly to stratified epithelia of the skin
and squamous epithelia of the upper gastrointestinal tract (Claas
et al, 1996). At the mRNA level, a very similar expression profile of
human (h) C4.4A was seen (Smith et al, 2001; Wu ¨rfel et al, 2001).
Recently, an antibody against hC4.4A and mouse (m) C4.4A was
described (Hansen et al, 2004). With this antibody, expression of
hC4.4A in placenta and skin was confirmed. In addition, mC4.4A
expression was found to become upregulated in migrating
keratinocytes during wound healing. In urothelium, too, C4.4A
was described as an inducible wound response gene (Smith et al,
2001).
Although C4.4A expression is rather restricted in non-trans-
formed tissues, C4.4A expression has been observed in several
tumour entities. hC4.4A mRNA was detected in cancer cell lines of
different origin including melanoma, breast, bladder and renal cell
carcinoma (RCC) as well as in tumour tissues of malignant
melanoma, breast cancer, lung carcinoma and lung tumour-
derived metastases, and primary and metastatic transitional cell
carcinoma of urothelial cell origin (Seiter et al, 2001; Smith et al,
2001; Wu ¨rfel et al, 2001; Fletcher et al, 2003). Notably, and in line
with the suggestion by Smith et al (2001) that C4.4A accounts for
an inducible wound response gene in urothelial cells, we observed
inducibility of the C4.4A gene (gene symbol: LYPD3) in malignant
melanoma (Seiter et al, 2001).
To further pursue the question of C4.4A as a potential tumour
marker, we generated hC4.4A-specific antibodies to characterize
the molecule as expressed under physiological conditions
and in tumour tissue. We provide evidence for differences in
C4.4A glycosylation, oligomer status and associated proteins.
We also show that C4.4A is released from tumour cells. Taking
the restricted expression in non-transformed tissue and high-level
expression in primary colorectal cancer and liver metastasis,
C4.4A might well be suited as a diagnostic colorectal cancer
marker.
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Tissues and tumour lines
Colorectal carcinoma, normal colorectal and colitis ulcerosa tissue,
liver metastasis of colorectal cancer and normal liver were
collected during surgery and snap-frozen in liquid nitrogen. The
mean age of patients with colorectal cancer (72 male and 25
female) was 64 and ranged from 38 to 90 years. A collection of
snap-frozen tissues from normal kidney and RCC as well as from
normal pancreatic gland, chronic pancreatitis and pancreatic
cancer has recently been described (Gesierich et al, 2005; Devitt
et al, 2006). The analysis of human healthy skin has been
performed with paraffin-embedded biopsy specimens, taken for
routine histopathology. Informed consent for tissue collection was
obtained from each patient and tissue collection was approved by
the University Ethics Review Board. The rat cell lines BSp73ASML
(ASML) (Zo ¨ller et al, 1978), Progressor (Reisser et al, 1993) and
804G (Izumi et al, 1981) were grown in RPMI medium
supplemented with 10% FCS. The embryonic kidney cell line
HEK-293 was grown in Iscove’s medium supplemented with 10%
FCS. The pancreatic adenocarcinoma lines BxPC3, Capan1,
Capan2, Colo357, MiaPaca2, Panc1, Panc89 and 8.18 were
maintained in RPMI 1640, supplemented with 10% FCS and
10mM sodium pyruvate. The colorectal cancer lines Colo205,
Colo320, Colo320DM, HT29, Lovo, SW480, SW707, SW948 and
WIDR were maintained in RPMI 1640 and supplemented with 10%
FCS. The origin of all these lines and the original depositors have
recently been summarized (Gesierich et al, 2005). The prostate
cancer cell lines LNCaP, PC-3 and DU145 were grown in RPMI
1640 and supplemented with 10% FCS. The breast cancer cell lines
MCF-7, MELN, HCC, MDA-MB4361, BT4TD were grown in DMEM
with 10% FCS. The HaCaT cell line (Boukamp et al, 1988) was
grown in DMEM with 10% FCS. All lines grew adherent and, when
confluent, were detached with trypsin for subculture. For the
evaluation of activation-dependent expression of C4.4A, tumour
lines were starved overnight in RPMI 1640 medium not containing
foetal bovine serum. Thereafter they were cultured for 24h in
medium containing 10% AB0 serum that was or was not heat-
inactivated for 30min at 561C (Seiter et al, 2001).
Cloning of expression constructs and transient
transfection of cells
A hC4.4A expression construct was generated by amplification of
the hC4.4A coding sequence (Wu ¨rfel et al, 2001) by PCR and
cloning in the pCDNA3.1 vector (Invitrogen, Karlsruhe, Germany).
HEK-293 cells were transiently transfected using the Polyfect
transfection reagent (Qiagen, Hilden, Germany) as described by
the manufacturer.
Antibodies
The following monoclonal and polyclonal antibodies were used:
C4.4 (mouse anti-rat C4.4A) (Matzku et al, 1989); CO-029 (anti-
human CO-029) (Sela et al, 1989); HEA125 (anti-human EpCAM)
(Momburg et al, 1987); anti-human uPAR (American Diagnostics,
New York, NY, USA); rabbit anti-galectin-3 (Santa Cruz, Santa
Cruz, CA, USA); biotin-conjugated anti-rabbit (Jackson Immuno
Research, West Grove, PA, USA); and anti-mouse HRP (horse-
radish peroxidase), anti-rabbit HRP, streptavidin-HRP and
anti-rabbit-phycoerythrin (PE) (all Dianova, Hamburg, Germany).
Anti-hC4.4A polyclonal antibodies were raised in rabbits immu-
nised with peptides QTPRQGVEHEASRDEEPRLTGGAAG and
LTSRALDPAGNESAYPPNGV coupled to keyhole limpet hemo-
cyanin (KLH). Antibodies were purified by passage of the antisera
over a Sepharose 4B column that had been coupled to the peptides
according to the manufacture’s protocol (Amersham Biosciences
Europe GmbH, Freiburg, Germany).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were deparaffinised by
two 5min washes in xylene, then rehydrated through successive
graded ethanol solutions and washed for 5min in PBS. Antigen
retrieval was achieved by immersing the slides in 0.01 M EDTA and
boiling for 10min in a water bath. Frozen sections were fixed 5min
in methanol/acetone (1:1). Endogenous hydrogen peroxidase
activity was quenched by treating the slides in 3% hydrogen
peroxidase/PBS for 10min followed by two washes in PBS. The
tissue was blocked in 10% BSA/PBS for 1h. To avoid background
staining due to the high content of mucus in colon and colorectal
cancer tissue, slides were, in addition, pre-incubated for 30min
with 2% serum corresponding to the species of the secondary
antibody before the addition of primary antibodies, which have
been used at half the concentration applied for staining of non-
colorectal tissue. Following three washes in PBS, the tissue sections
were incubated with biotin-conjugated secondary antibody (Jackson
ImmunoResearch) (5mgml
 1, 30min) and alkaline phosphatase-
conjugated avidin–biotin complex (Vector Laboratories, Grun-
berg, Germany) solutions (5min). Tissue sections were counter-
stained with Mayer’s haematoxylin. Staining was assessed semi-
quantitatively by two independent observers according to the
following score: no stained cells:  ; weak staining or staining of
less than 25% of cells: ±/0.5; moderate staining or staining of less
than 50% of cells: þ/1; moderate to strong staining of mostly
450% of cells: þþ/2; strong staining of 475% of cells: þþþ/3.
Tissues were considered as positive when both observers scored
the tissue section as þ/1. As far as the judgement of the two
observers differed, new sections were stained and re-evaluated.
These tissues were only considered as positive when both
observers judged the repeated staining with þ/1. As far as the
judgement of both observers differed again, the tissue sample was
not included in the final evaluation.
FACS analysis
Flow cytometry followed routine procedures using 1 3 10
5
tumour cells per sample. Trypsinized cells were allowed to recover
for 2h at 371C in RPMI 1640 with 10% FCS. The primary antibody
was used at a concentration of 5mgml
 1 and was replaced by
normal rabbit IgG in the negative control. The secondary antibody
was PE- or APC-labelled. Samples were analyzed using an
FACS Calibur and the Cell Quest Program (Becton Dickinson,
Heidelberg, Germany).
Immunoprecipitation
Cells (1 10
7) were surface-biotinylated with 1mgml
 1 biotin-
X-NHS WS (Calbiochem, San Diego, CA, USA) in HEPES puffer
(25mM HEPES, 150mM NaCl, 5mM MgCl2 (pH 7.4)) for 30min at
room temperature and lysed for 1h at 41C in 4ml HEPES puffer
with 1% Triton X-100 and a protease inhibitor cocktail (Roche
Diagnostics GmbH, Mannheim, Germany). After centrifugation for
30min at 20000g, lysates (1ml) were precleared by incubation
with 1/10 volume protein G-Sepharose for 2h at 41C. Pre-cleared
lysates were incubated 3h at 41C with 1mg of antibody or control
IgG. Immune complexes were washed four times with lysis buffer
and precipitated proteins were analyzed by SDS–PAGE, followed
by western blot (WB).
Western blot
Proteins were resolved in 12% SDS–PAGE under non-reducing or
reducing conditions and the proteins were transferred to PVDF
membrane at 30V overnight. After blocking (5% fat-free milk
powder in PBS), membranes were incubated with streptavidin-
HRP or with the indicated primary antibodies, followed by
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enhanced chemiluminescence detection system (Amersham Bio-
sciences Europe GmbH).
Galectin-3 pull-down
Glutathione-S-transferase (GST)-galectin-3 was purified as de-
scribed previously (Paret et al, 2005). For the GST pull-down, GST-
galectin-3 fusion protein and GST, respectively, were immobilized
on glutathione (GSH)-sepharose beads and allowed to interact for
2h at 41C with whole-cell lysate from the indicated cell lines.
Following binding, GSH-sepharose beads were washed extensively
with PBS containing 1% Triton X-100 and proteins were released
by addition of 100mM lactose. Released proteins were analysed by
SDS–PAGE followed by WB. Where indicated, released proteins
were deglycosylated before loading on SDS–PAGE gel.
Detection of released C4.4A
Microvesicles were prepared by multi-step centrifugation. Cell
culture supernatants were centrifuged two times at 800g, followed
by centrifugation at 1600 and 6000g. Finally, microvesicles were
precipitated by ultracentrifugation at 200000g and resuspended in
PBS. Were indicated, microvesicles were subjected to deglycosyla-
tion before further analysis. Phase separation of C4.4A in Triton
X-114 was performed as follows. After multi-step centrifugation
(800, 1600 and 6000g), cell culture supernatant was immunopre-
cipitated with C4.4 antibody. Immunoprecipitated C4.4A was
eluted from the protein G-antibody complex using 100mM glycine
at pH 2. After neutralisation, the solution was adjusted to 2%
Triton X-114 and incubated for 1h at 41C. Samples were cleared by
centrifugation at 20000g for 10min at 41C. The supernatant was
incubated for 5min at 371C. The detergent-rich and aqueous
phases were separated by centrifugation for 5min at 20000g at
room temperature. Detergent-rich and aqueous phases were
adjusted to identical volumes using PBS and analyzed for the
presence of C4.4A by SDS–PAGE followed by WB.
Trypsin digestion
Recombinant rC4.4A (rrC4.4A) carrying a myc tag at the C
terminus (Paret et al, 2005) was digested for 2h at 371C with
trypsin at the indicated concentrations.
Deglycosylation
In vivo deglycosylation was performed by adding tunicamycin
(SIGMA, Steinheim, Germany) at 5mgml
 1 to the cell culture
medium overnight. For in vitro deglycosylation, cell lysates,
immunoprecipitates, microvesicles or precipitates after pull-
down were incubated for 16h at 371C with N-glycosidase
F (20Uml
 1; ROCHE, Mannheim, Germany) and/or O-glycosidase
(2.5U100ml
 1; ROCHE) and/or neuraminidase (0.05Uml
 1;
SIGMA) in PBS containing 1% Triton X-100 before analysis by
SDS–PAGE.
Statistics
According to the specific question, association between quantita-
tive and ordered variables was quantified by Spearman’s rank
correlation; the Jonckheere–Terpstra test for trend was used to
investigate a trend in proportions; and the Wilcoxon rank sum test
was used for two-group comparisons of quantitative variables. The
signed rank test was used to compare paired quantitative
observations. All tests were performed two-sided to the 0.05 level.
Ninety-five percent confidence intervals were calculated for mean
score differences. Sensitivity was defined as true positive (true
positive plus false negative) and specificity as true negative (true
negative plus false positive). The true positive rate is defined as the
percentage of marker-positive tumour samples, the false positive
rate is the percentage of marker-positive control samples, the true
negative rate is the percentage of marker-negative control samples
and the false negative rate is the percentage of marker-negative
tumour samples. Sensitivities and specificities of different markers
were compared by the w
2-test. All calculations were performed
using SAS version 9.1 (SAS Institute Inc. Corp, NC, USA).
RESULTS
Characterisation of rabbit polyclonal antibodies against
hC4. 4A peptides
Antibodies were generated by vaccination of rabbits with KLH-
coupled hC4.4A peptides located at the C terminus (anti-hC4.4A-C)
and N terminus (anti-hC4.4A-N) (Figure 1A). The hC4.4A peptides
were coupled to sepharose, and C4.4A-specific antibodies were
isolated from the antisera by passage over the peptide-coupled
sepharose. The specificity of the antibodies was further verified by
transfecting HEK-293 cells with hC4.4A cDNA. hC4.4A expression
was analysed by WB. Only HEK-293 cells transfected with the
hC4.4A cDNA showed a band of the expected size, whereas no
reactivity was observed with lysates of HEK-293 cells transfected
with the empty vector (Figure 1B). The anti-hC4.4A-C antibody
stained paraffin-embedded specimens of healthy human skin,
where expression of hC4.4A was restricted to the stratum
granulosum. No staining was seen in the sections using a control
IgG (Figure 1C). Both antibodies recognised the hC4.4A protein in
WB in the immortalized keratinocyte line HaCaT (Figure 1D),
which had been shown before by in situ hybridization to be C4.4A-
positive (Wu ¨rfel et al, 2001).
Expression of hC4.4A in cancer lines
C4.4A expression on cancer cell lines was revealed by flow
cytometry using the anti-hC4.4A-C antibody. Five breast, three
prostate, five of eight pancreas and five of nine colorectal cancer
lines were positive for hC4.4A (Table 1). Because C4.4A, similar to
uPAR expression (Mazumdar et al, 2001), has been described to
become upregulated or induced by, for example, heat-labile serum
factors (Seiter et al, 2001), expression of C4.4A on colorectal
cancer lines was re-evaluated after cells had been cultured for 24h
in the presence of fresh AB0 serum. Expression in the C4.4A-
positive lines mostly remained unaltered, but C4.4A expression
was induced by heat-labile serum factors in colorectal cancer lines
that in the resting state did not or very weakly express C4.4A
(Table 1 and Figure 2A). hC4.4A expression was confirmed by
immunoprecipitation of biotinylated lysates (Figure 2B, left),
which revealed significant differences in the molecular weight of
hC4.4A. The band indicated with arrow 3 corresponds in the
molecular weight to the monomeric form of hC4.4A. Changes in
the molecular weight of this band between different cell lines are
probably due to differences in the glycosylation state. After in vivo
deglycosylation with tunicamycin, an inhibitor of N-glycosylation,
a band of about 50kDa is detectable by WB analysis in MCF-7 and
BxPC3 cell lysates using the anti-hC4.4A-N antibody. A size
reduction was also observed after in vitro deglycosylation with
N-glycosidase F of immunoprecipitated hC4.4A from the MCF-7
cell line (Figure 2E). The expected size of the protein as calculated
from the amino-acid composition is 32kDa. Thus, O-glycosyla-
tions likely account for the difference to the expected size. In the
presence of O-glycosidase alone, protein size was unchanged (data
not shown), indicating that O-glycosylations carry sialic acid
modifications. Indeed, in the presence of neuraminidase and
O-glycosidase, the protein size was reduced to a broad band of
35–40kDa (Figure 2E).
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MCF-7 and BxPC3 cells is not recognized by both antibodies in
WB, as demonstrated for hC4.4A-N (Figure 2D), but both
antibodies reacted well with hC4.4A on the HaCaT cell line
(Figure 1D). Because the hC4.4A-N antibody did react with the
tumour line lysates after N-deglycosylation, it is likely that C4.4A
glycosylation differs in HaCaT cells and the tested tumour lines,
where in the latter the binding sites may be masked by
glycosylation. Flow cytometry analysis of C4.4A expression in
colorectal cancer lines was also repeated after O- and N-
deglycosylation. In most lines, staining intensity was at least
slightly increased after O- or N-deglycosylation. Staining intensity
was most strongly increased after N-deglycosylation of Colo205
and after O-deglycosylation of Lovo (data not shown).
We previously described that rat C4.4A interacts with galectin-3
(Paret et al, 2005). Because binding depends on the carbohydrate
residues of C4.4A, we wondered if all glycosylation forms of C4.4A
bind galectin-3. In fact, only 5 of 7 human cancer cell lines express
a C4.4A isoform, which allows galectin-3 binding (Figure 2F).
Immunoprecipitation of biotinylated human cancer cells with
anti-hC4.4A-N uncovered additional features that differed between
the individual lines. The higher molecular weight band, seen with
MCF-7, Colo357 and, albeit weakly, with DU145 and LNCaP cell
lysates (Figure 2A, arrow 1) possibly is a C4.4A oligomer, because
it disappears after reduction with 2-mercaptoethanol (2-ME) as
demonstrated for MCF-7 and Colo357 (Figure 2B). Moreover, in
the presence of 2-ME, the monomeric form of Colo357 and MCF-7
runs at a slightly higher molecular weight. This could be due to the
reduction of the disulphide bridges contained in the two Ly-6
domains and the loss of the three-dimensional folding. Interest-
ingly, the putative C4.4A oligomer was detected only in cancer cell
lines, which according to the flow cytometry analysis displayed
high hC4.4A expression. A band of about 100kDa (Figure 2A and
B, arrow 2) could represent a highly glycosylated form of hC4.4A
or an interacting protein. The latter is more likely, because the
band is still visible after deglycosylation (Figure 2D). Two
additional co-immunoprecipitating proteins of about 38 and
25kDa were detected in the precipitate of the HaCaT cell line
Table 1 hC4.4A expression in human cancer cell lines (flow cytometry)
C4.4A expression
Pancreatic
cancer Intensity
a
Colorectal
cancer
Intensity
a
unstimulated
Intensity
a
stimulated
b Breast cancer Intensity
a
Prostate
cancer Intensity
a
Colo357 +++ SW480 + + MCF-7 +++ LNCaP +++
Capan2 ++ Colo205 + + MELN +++ Du145 +++
Panc89 ++ HT29   + HCC1937 ++ PC3 +
BxPC3 + WIDR   + BT47D ++
MiaPaca2 + Colo320   + MDA-MB436 +
Panc1   Colo320DM + +
8.18   SW707   +
Capan1   SW948 ++ ++
Lovo ++ ++
aFlow cytometry data were analysed according to the increase in the mean fluorescence intensity as compared to the negative control (normal rabbit IgG plus anti-rabbit IgG-PE):
–(negative), intensity 1.0- to 1.5-fold; + (distinct), intensity 1.5- to 4-fold; ++ (strong), intensity 4- to 10-fold; +++ (very strong), intensity 410-fold.
bCells were starved
overnight and thereafter incubated for 24h in RPMI 1640 containing 10% fresh AB0 serum.
Anti-hC4.4A-N
Anti-hC4.4A-C
H
E
K
-
2
9
3
H
E
K
-
2
9
3
-
h
C
4
.
4
A
H
E
K
-
2
9
3
H
E
K
-
2
9
3
-
h
C
4
.
4
A
hC4.4A-C hC4.4A-N IgG
H
E
K
-
2
9
3
-
h
C
4
.
4
A
h
C
4
.
4
A
-
C
h
C
4
.
4
A
-
N
R
a
b
b
i
t
 
I
g
G
WB:
170 kDa
130 kDa
100 kDa
72 kDa
55 kDa
40 kDa
170 kDa
130 kDa
100 kDa
72 kDa
55 kDa
40 kDa
33 kDa
24 kDa
HaCaT
WB:
A
B
CD
Figure 1 Production of antibodies against hC4.4A. (A) Schematic representation of the structure of hC4.4A. Circles represent the Ly-6 domains. Parts of
the molecule recognised by the antibodies are in red. (B) HEK-293 cells were transfected with cDNA coding for hC4.4A (HEK-293-hC4.4A) or with vector
alone (HEK-293). Lysates were analysed in WB with anti-hC4.4A-C (left) and anti-hC4.4A-N (middle). The right lane shows HEK-293-hC4.4A lysates
blotted with rabbit IgG. (C) Immunohistochemistry of paraffin-embedded, normal healthy skin using rabbit IgG (negative control) and anti-hC4.4A-C at the
concentration of 1.5mgml
 1. Scale bar¼50mm. (D) Western blot of HaCaT cell lysate with anti-hC4.4A-C (left), anti-hC4.4A-N (right) and rabbit IgG
(middle) (negative control).
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lysates (arrow 4 and 5). Because cells were labelled with membrane
impermeable biotin, these two interacting proteins are likely
membrane-associated. Identification of these associating proteins
that are absent or very weakly expressed in tumour lines is in
progress.
Taken together, human tumour cell lines frequently express
highly glycosylated C4.4A, which obviously can prevent binding
of the antibodies generated by peptide vaccination and can also
interfere with the association of galectin-3 with C4.4A. High C4.4A
expression can also lead to oligomer formation. The consequences
of the glycosylation-prohibited associations as well as of oligomer
formation on the function of C4.4A remain to be explored.
Expression of C4.4A and galectin-3 in colorectal,
pancreatic and RCC
C4.4A expression was evaluated in frozen specimen of colorectal
cancer, liver metastasis of colorectal cancer, pancreatic adenocar-
cinoma and RCC by immunohistochemistry. Normal colon and
normal liver do not (98 and 97%, respectively) or very weakly (2
and 3%, respectively) express hC4.4A. Yet, 480% of colon cancer
and 470% of liver metastasis show distinct to strong staining.
Importantly, C4.4A expression was not induced in inflamed (colitis
ulcerosa) tissue of the colon. While kidney and pancreatic gland
tissue also did not or weakly express C4.4A, C4.4A expression was
observed in 47% of RCC and 53% of pancreatic adenocarcinoma.
However, C4.4A expression was also seen in 40% of chronic
pancreatitis tissue (Table 2A). To validate the reliability of C4.4A
as a tumour marker, particularly for colorectal cancer, expression
of C4.4A was compared with galectin-3, EpCAM and CO-029
expression, that all three have been described to be upregulated in
colorectal cancer (Sela et al, 1989; Armstrong and Eck, 2003; Nagy
et al, 2003). In primary colorectal cancer, the sensitivity for C4.4A
was 0.85 (95% CI: 0.73–0.84) and the specificity 1.00 (95% CI:
0.94–1.00). The sensitivity for galectin-3 was 0.79 (95% CI: 0.70–
0.87) and the specificity 0.97 (95% CI: 0.91–0.99). The sensitivity
for EpCAM was 0.94 (95% CI: 0.87–0.98) and the specificity 0.80
(95% CI: 0.71–0.87). The sensitivity for CO-029 was 0.98 (95% CI:
0.92–1.00) and the specificity 0.94 (95% CI: 0.86–0.98) (Kuhn
et al, 2007). Thus, sensitivity of EpCAM was slightly (P¼0.08) and
of CO-029 was significantly higher (P¼0.004) than for C4.4A.
However, the specificity of EpCAM was significantly reduced
compared with C4.4A (P¼0.002). The corresponding values for
liver metastasis of colorectal cancer are C4.4A: 0.79 sensitivity
(95% CI: 0.63–0.90), 1.00 specificity (95% CI: 90–100%); galectin-
3: 0.83 sensitivity (95% CI: 0.70–0.91), 1.00 specificity (95% CI:
0.94–1.00); EpCAM: 0.93 sensitivity (95% CI: 0.83–0.98), 0.91
specificity (95% CI: 0.81–0.97); and CO-029: 0.94 sensitivity (95%
CI: 0.85–0.99), 0.94 specificity (95% CI: 0.85–0.99) (Kuhn et al,
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s2007). Accordingly, in liver metastasis of colorectal cancer, the
sensitivity of EpCAM and CO-029 also was significantly higher
than for C4.4A (P¼0.04 and 0.02, respectively). The specificity of
EpCAM was slightly reduced compared with C4.4A.
There have been too few colitis ulcerosa tissues to warrant
statistical analysis. It should, however, be mentioned that, distinct
to C4.4A (Table 2A), galectin-3 expression was variable in colitis
ulcerosa. Three out of six tissue samples showed no staining, two
samples were weakly stained and one sample was distinctly stained
(data not shown).
Staining of ductal cells of the pancreatic gland with anti-CO-029
had been observed in 50% and of pancreatic cancer tissue in 100%
(Gesierich et al, 2005). EpCAM expression was not only seen in
87% of pancreatic adenocarcinoma, but also in 87% of the
pancreatic gland. However, pancreatic gland tissue was not stained
by anti-uPAR, a marker discriminating between chronic pancrea-
titis and pancreatic adenocarcinoma (Chen et al, 2007), whereas
67% of pancreatic adenocarcinoma were stained. The data
correspond to sensitivity values of C4.4A: 0.53, galectin-3: 0.80,
EpCAM: 0.87, CO-029: 1.00 and uPAR: 0.67. Accordingly, the
sensitivity of galectin-3 (P¼0.03), EpCAM (P¼0.005) and CO-029
(Po0.0001) was significantly higher than the sensitivity of C4.4A.
However, the specificity of galectin-3 (0.75) was equal (P¼1), and
the specificity of EpCAM (0.13) (P¼0.0004) and CO-029 (0.50)
(P¼0.02) was significantly lower than that of C4.4A (1.00).
Urokinase receptor also showed a sensitivity of 1.00.
Also, 38% of RCC sections, which differentially express uPA and
uPAR (Bhuvarahamurthy et al, 2005), were stained by anti-uPAR;
kidney sections were not stained. Thus, uPAR and C4.4A showed a
specificity value of 1.00. The sensitivity values of 0.57 for C4.4A
and 0.38 for uPAR differed significantly (P¼0.009).
It should be kept in mind that we used suboptimal concentra-
tions of all antibodies for the staining of colonic mucosa and
colorectal cancer tissue to avoid unspecific staining. As we
observed staining of colorectal cancer tissue with all four
antibodies in 79–98%, it implies that irrespective of the possible
underestimate particularly of EpCAM and galectin-3 expression in
normal tissue, expression of these four molecules is significantly
upregulated in colorectal cancer such that expression in primary
colorectal cancer and that in liver metastasis differ at a highly
significant level from expression in the corresponding normal
tissue. For C4.4A expression, this also accounts for the comparison
to inflamed tissue (Table 2A and B).
Finally, we want to point out, as exemplified in Figure 3, that
C4.4A expression was restricted to the tumour cell membrane.
Galectin-3 was predominantly expressed in the tumour cells, but
Table 2 Expression of C4.4A in colorectal, pancreatic and renal cell carcinoma
(A) Comparison between tumour and non-transformed tissue
% stained samples
a
Tissue
No. of
samples Negative ( ) Weak (±)
Distinct (+)
C4.4A Strong (++)
Very strong
(+++) P-value
y
Colonic mucosa 61 98.4 1.6 0.0 0.0 0.0
Colitis ulcerosa 6 100.0 0.0 0.0 0.0
Colorectal carcinoma 55 7.3 7.3 23.6 32.7 29.1 o0.0001
Liver 35 97.1 2.9 0.0 0.0 0.0
Liver metastasis 38 13.2 7.9 31.6 31.6 15.8 o0.0001
Pancreatic gland 8 62.5 37.5 0 0 0
Chronic pancreatitis 10 40.0 20.0 10.0 20.0 10.0
Pancreatic carcinoma 30 26.7 20.0 40.0 10.0 3.3 0.01
Kidney 10 70.0 30.0 0.0 0.0 0.0
Renal cell carcinoma 61 21.3 21.3 31.1 16.4 9.8 NS
(B) Comparison between different tumour markers
Marker
Parameter C4.4A Galectin-3
w EpCAM
b,w CO-029
b,w UPAR
w
Colorectal cancer
No cancer tissue 55 100 100 93
No control tissue 61 100 100 93
Sensitivity
c 0.85 0.79 (NS) 0.94 (NS) 0.98 (0.004)
Specificity
c 1.00 0.97 (NS) 0.80 (0.0002) 0.94 (0.045)
Liver metastasis
No cancer tissue 38 57 57 54
No control tissue 35 57 57 54
Sensitivity 0.79 0.83 (NS) 0.93 (0.04) 0.94 (0.02)
Specificity 1.00 1.00 (NS) 0.91 (NS) 0.94 (NS)
Pancreatic cancer
No cancer tissue 30 30 30 30 30
No control tissue 8 8 8 8 8
Sensitivity 0.53 0.80 (0.03) 0.87 (0.005) 1.00 (0.00002) 0.67 (NS)
Specificity 1.00 0.75 (NS) 0.13 (0.0004) 0.50 (0.02) 1.00 (NS)
Renal cell carcinoma
No cancer tissue 61 61
No control tissue 10 10
Sensitivity 0.57 0.38 (0.009)
Specificity 1.00 1.00 (NS)
C4.4A in colorectal cancer
C Paret et al
1151
British Journal of Cancer (2007) 97(8), 1146–1156 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
swas also detected in the tumour stroma of some tissue samples. In
colitis ulcerosa, galectin-3 expression was restricted to stromal
cells (Figure 3).
Considering C4.4A expression in pancreatic cancer and RCC, the
sensitivity values of 0.53 and 0.57 rather excluded C4.4A in these
tumour entities as a diagnostic marker. Therefore, additional
statistical analyses on a potential correlation between C4.4A and
galectin-3 expression and clinical parameters of grading, staging and
disease-free survival were performed only for colorectal cancer and
liver metastases derived thereof. As could have been expected by the
high frequency and the high level of C4.4A and galectin-3 expression
in colorectal cancer, expression of both molecules did not become
upregulated at a statistically significant level in dependence on
tumour staging, the involvement of lymph nodes and distant organs.
C4.4A and galectin-3 expression also did not significantly vary
depending on tumour grading (Table 2C). Finally, C4.4A and
galectin-3 expression did not correlate at a statistically significant
level with the disease-free survival (Table 2D).
C4.4A is released in the supernatant of cancer cells lines
The C4.4A-related uPAR molecule mostly is shed without a GPI
anchor (Ploug et al, 1992; Wilhelm et al, 1999), but uPAR
fragments have also been described (Sidenius et al, 2000; Montuori
et al, 2005; Beaufort et al, 2007); uPAR with an intact GPI anchor is
also detected in shed membrane vesicles (Wilhelm et al, 1999). To
analyse whether C4.4A is present in shedded membrane vesicles,
supernatant of two rat and five human tumour lines was subjected
to multi-step centrifugation for elimination of cell debris followed
by ultracentrifugation to collect membrane vesicles. The rat
tumour lines were included because the rat, different from the
human C4.4A-specific antibodies, has been shown to recognize
C4.4A indendently of gylcosylation and, in addition, is well suited
for immunoprecipitation (Matzku et al, 1989; Ro ¨sel et al, 1998).
C4.4A was found in the vesicles containing pellet of all lines
(Figure 4A). To see whether the GPI anchor is cleaved during
C4.4A release, ASML supernatant was concentrated and
(C) Correlation to colorectal tumour grading and staging
Primary tumour
No. of
samples
C4.4A % stained
(mean staining intensity)
d P-value
+
No. of
samples
Galectin-3 % stained
(mean staining intensity)
d P-value
+
Primary tumour staging
T0–1 4 100 (2.00) NS 6 100 (1.50) NS
T2 11 100 (2.50) 22 100 (1.75)
T3 25 84.0 (1.68) 49 91.8 (1.73)
T4 15 100.0 (1.68) 20 95.0 (1.74)
Lymph node staging
N0 35 94.3 (1.51) NS 61 96.7 (1.66) NS
N1 12 91.7 (1.90) 23 100.0 (1.77)
N2 8 87.5 (1.42) 13 76.9 (1.55)
Metastasis staging
M0/mix 43 93.0 (1.62) NS 74 95.6 (1.69) NS
M1 12 91.7 (1.85) 23 91.3 (1.81)
Primary tumour grading
G0/G1 2 100.0 (2.20) NS 5 100.0 (1.83) NS
G2 44 90.9 (1.86) 72 94.4 (1.72)
G3/G4 9 88.9 (1.83) 20 95.0 (1.74)
(D) Correlation to the disease-free survival in colorectal cancer patients
Disease-free survival
(months)
No. of
samples
C4.4A % stained
(mean intensity of staining)
d P-value
yy
No. of
samples
Galectin-3 % stained
(mean intensity of staining)
d P-value
yy
Primary tumour
0 13 84.6 (1.86) NS 26 92.3 (1.81) NS
Undefined 42 92.9 (1.61) 71 98.8 (1.70)
Liver metastasis
0 11 100 (1.44) NS 20 90.0 (1.73) NS
1–24 17 94.1 (1.44) 22 90.9 (1.43)
424 9 88.9 (1.55) 15 93.3 (1.43)
NS¼not significant.
aMean intensity of staining was estimated as indicated in Materials and Methods; samples classified as   or ± were considered negative, samples classified as
+, ++ and +++ were considered as positive.
bPart of these analyses has already been described (Gesierich et al, 2005; Kuhn et al, 2007).
cSample with a score of   and ± were
considered as negative; samples with a score of +, ++ and +++ were considered as positive; sensitivity¼true positive: (true positive + false negative); specificity¼true negative:
(true negative + false positive).
dMean intensity of staining was estimated as indicated in material and methods, e.g. a score of ± was taken as 0.5 and a score of +++ as 3.
ySigned rank test; for pancreatic adenocarcinoma, Wilcoxon rank sum test.
wP-value¼w
2-test.
+The correlation between marker expression and tumour staging, lymph node
staging, metastasis staging and tumour grading was calculated by the Jonckheere–Terpstra test for trend. No significant differences were observed.
yyExpression of C4.4A and
galectin-3 did not differ significantly (Wilcoxon rank sum test) in primary tumours of patients who had developed liver metastasis concomitantly with the primary tumour of those
who had not. In liver metastasis C4.4A and galectin-3 expression did not correlate with the disease-free survival.
C4.4A in colorectal cancer
C Paret et al
1152
British Journal of Cancer (2007) 97(8), 1146–1156 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
simmunoprecipitated after cell debris elimination. The immunopre-
cipitate was subjected to Triton X-114 extraction. Triton X-114-
containing solutions are homogenous at 41C, but separate into
detergent-rich and aqueous phases at 371C. Glycosylphosphatidy-
linositol anchor containing C4.4A, probably vesicle-associated, parti-
tioned into the detergent-rich phase (Figure 4B, left). However, the
major part of released rC4.4A partitioned into the aqueous phase
(Figure 4B, right), indicating GPI anchor hydrolysis and removal of
the hydrophobic portion of the anchor. In the water-soluble
fraction, an additional rC4.4A fragment of about 40kDa was
detected (Figure 4B), which could represent a proteolytic cleavage
product of C4.4A. To support this hypothesis, rrC4.4A carrying a
myc tag at the C terminus was digested with trypsin. Thereafter, the
proteins were separated by SDS–PAGE and blotted with C4.4 and
anti-myc. Trypsin-treated rrC4.4A revealed a 40kDa protein, when
blotted with C4.4. Only the undigested rrC4.4A was detected with
the anti-myc antibody, indicating that the fragment represents the
N-terminal part of C4.4A (Figure 4C). In fact, a protease-sensitive
region between domains 2 and 3 of C4.4A has recently been
described (Hansen et al, 2004). Thus, similar to uPAR, cancer cells
release C4.4A with its GPI anchor in shed vesicles, as soluble, GPI
anchor cleaved molecule and as fragments thereof.
DISCUSSION
The GPI-anchored C4.4A glycoprotein was first identified in a
highly metastasizing rat pancreatic adenocarcinoma line (Matzku
et al, 1989). The possible importance of the protein as tumour
marker was indicated by the restricted expression in normal
tissues (Ro ¨sel et al, 1998; Smith et al, 2001; Wu ¨rfel et al, 2001) and
upregulation of C4.4A mRNA in different tumours (Seiter et al,
2001; Smith et al, 2001; Fletcher et al, 2003). We here report
hC4.4A protein expression in several tumour lines and tumour
tissues and provide first evidence suggestive for C4.4A as a
possible serum marker for cancer diagnosis.
Glycosylation, oligomer formation and interaction
partners of C4.4A in human tumour lines
Two polyclonal antibodies were raised against peptides localised at
the C terminus and between domains 1 and 2, respectively, of
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Figure 4 Release of rat and human C4.4A. (A) Supernatant of the
indicated cell lines was subjected to ultracentrifugation. The pellets were
separated by SDS–PAGE and blotted with C4.4 (left) or anti-hC4.4A-N
(right). For analysis with hC4.4A-N, pellets were treated with N-glycosidase
F before SDS–PAGE. C4.4A was recovered in the pellet (vesicles
containing uncleaved C4.4A). (B) Supernatant of ASML cells was subjected
to IP with C4.4. Bound proteins were eluted and extracted with Triton X-
114. The Triton X-114 fraction (left) and the aqueous fraction (right) were
separated by SDS–PAGE and blotted with C4.4. The Triton X-114 fraction
contained a considerable amount of C4.4A (GPI anchor-containing C4.4A).
Two bands of about 80–90 and 40kDa were recovered from the aqueous
fraction, the lower molecular weight band indicating a proteolytic cleavage
product of C4.4A. (C) Rat recombinant C4.4A with a C-terminal myc tag
was treated for 2h at 371C with 0.01 or 0.1% trypsin. After SDS–PAGE of
the undigested and trypsin-digested rrC4.4A protein, blots were incubated
with C4.4 (left) and anti-myc (right). The undigested 90kDa recombinant
protein was detected with both C4.4 and anti-myc. Only C4.4 recognized a
fragment of about 40kDa.
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shuman C4.4A. The antibody against the C terminus stained the
stratum granulosum of healthy human skin. A recently described
polyclonal hC4.4A-specific antibody that cross-reacts with mC4.4A
stained the suprabasal layer of the epidermis (Hansen et al, 2004).
In the rat, C4.4A is strongly expressed by basal keratinocytes,
which are in contact with the extracellular matrix, and staining
decreases in suprabasal keratinocytes. These different staining
profiles might be due to species differences. It is also possible that
differences are due to the epitopes recognized by the different
antibodies. Only for the generation of the monoclonal anti-rC4.4A
antibody, mice were vaccinated with cell membranes (Matzku et al,
1989). This antibody obviously recognizes an epitope that does not
become hidden by glycosylation (Ro ¨sel et al, 1998). Instead, a
recombinant protein vaccination-derived antibody (Hansen et al,
2004) and our peptide vaccination-derived antibodies did not stain
basal keratinocytes. However, these antibodies stained HaCaT
cells. Because glycosylation of C4.4A shows great variability and
glycosylation of keratinocytes depends on the differentiation status
(Mehul et al, 2003), it becomes likely that the restricted epidermal
staining patterns by distinct anti-C4.4A antibodies are a con-
sequence of C4.4A glycosylation that may hide the respective
epitopes.
In fact, C4.4A carries N- and O-glycosylation sites, where the
O-glycosylations are modified by sialic acid. Interestingly, while
hC4.4A was detected by WB in HaCaT cell lysate, both antibodies
did not react in WB with hC4.4A in cancer cell lines, but the
hC4.4A-N antibody did so after deglycosylation. The finding
suggests that C4.4A glycosylation differs between tumour cell lines
and the immortalized keratinocyte line HaCaT, such that binding
sites for anti-hC4.4A-N and probably anti-hC4.4A-C are frequently
masked by sugar chains in tumour lines. Indeed, the peptide
recognised by the anti-hC4.4A-N antibody has a potential N-
glycosylation site at AA position 129 and the peptide recognised by
the anti-hC4.4A-C antibody is near a potential O-glycosylation site
(Hansen et al, 2004). We previously described that C4.4A interacts
with galectin-3 (Paret et al, 2005), which is associated with
colorectal cancer progression (Schoeppner et al, 1995; Nakamura
et al, 1999; Endo et al, 2005). The interaction of galectin-3 with
its cellular ligands depends on the glycosylation status of the
interaction partner (Barondes et al, 1994). In fact, some of the
glycosylated forms of hC4.4A as expressed on cancer cells did not
bind galectin-3. Whether, indeed, differences in the C4.4A
glycosylation state account for the distorted interaction with
galectin-3 remain to be elucidated. However, altered glycosylation
in cancer can play an important role in tumour cell adhesion
and migration (Orntoft and Vestergaard, 1999), as well as in
extravasation via interaction with galectin-3 on endothelial cells
(Lehr and Pienta, 1998; Glinsky et al, 2000; Krishnan et al, 2005).
Two additional membrane proteins that associate with C4.4A in
HaCaT cells, but very rarely in tumour cells as well as a high
molecular weight protein, mainly detected in MCF-7 cells, remain
to be identified.
C4.4A likely can form oligomers, which are not detected after
2-ME treatment and are reduced in size after deglycosylation.
Because oligomers were only detected in cells, which according to
flow cytometry analysis expressed C4.4A at a high level, the
monomer/oligomer status may depend on the expression level.
Furthermore, oligomers disappeared in the presence of
b-mercaptoethanol. Thus, they are possibly formed via disulfide
bridges. Alternatively, the native conformation of the molecule is
required for oligomerisation. Expression level and oligomerisation
of uPAR determine whether uPA elicits an adhesive or migratory
response (Chiaradonna et al, 1999), high level uPAR expression
contributes to tumorigenicity and invasiveness (Aguirre Ghiso
et al, 1999), and oligomerisation of uPAR is required for
vitronectin binding (Wei et al, 1994; Sidenius et al, 2002). Whether
the expression level of C4.4A and oligomerisation also has
functional consequences remains to be explored.
C4.4A as a candidate marker for the diagnosis of colorectal
cancer
C4.4A is expressed at distinct to high levels in primary colorectal
cancer as well as in liver metastasis in more than 80% of the
patients with negligible expression in normal colonic mucosa and
normal liver. Importantly, C4.4A expression was also largely
absent in inflamed colonic mucosa and liver. C4.4A expression was
compared with the expression of EpCAM, galectin-3 and CO-029,
which have been described as reliable markers in colorectal cancer
(Sela et al, 1989; Armstrong and Eck, 2003; Nagy et al, 2003). With
respect to sensitivity, EpCAM (liver metastases, only) and CO-029
were superior to C4.4A. However, with respect to specificity, C4.4A
proved to be superior to EpCAM and CO-029.
Notably, too, frequency and intensity of C4.4A expression
apparently did not vary at a statistically significant level in
dependence on tumour grading and staging, nor between primary
tumours and metastasis. Therefore, one could argue that C4.4A
expression is induced early during tumorigenesis and remains
stable. However, our data do not allow to exclude upregulation
during tumour progression. First, immunohistochemistry is a
semi-quantitative method; second, we experienced that very high
C4.4A expression can be accompanied by oligomerisation, which
may prohibit recognition by the available antibodies; third, the
antibodies also do not bind to highly glycosylated C4.4A. The fact
that we observed at the RNA level a clear upregulation of C4.4A
expression at the tumour boundary and in metastatic tissue of
malignant melanoma (Seiter et al, 2001) rather argues for C4.4A
expression levels to be regulated also in tumour tissue, which
possibly becomes hidden by modifications of the molecule that
prevent recognition by the available antibodies. Nonetheless, the
high frequency of C4.4A expression in colorectal cancer and liver
metastasis makes the molecule a candidate marker in the diagnosis
of colorectal cancer.
Despite the high frequency of C4.4A expression in primary
tumours and liver metastases, C4.4A expression was noted only in
5 of 9 colorectal cancer lines. This feature is in line with the notion
that C4.4A expression is strictly regulated (Seiter et al, 2001; Smith
et al, 2001; Hansen et al, 2004), requires a C/EBPb/JunD or c-Jun
complex for induction of transcription (Fries et al, 2007) and can
also be induced in tumour lines by not yet defined heat-labile
serum factors (Wu ¨rfel et al, 2001). These stimuli will be present
in vivo, but be missed in culture. In fact, de novo C4.4A expression
was seen in colorectal cancer lines after starving and culturing in
fresh serum.
We also evaluated C4.4A expression in pancreatic cancer tissue,
which had been tested before for CO-029 expression (Gesierich
et al, 2005). C4.4A expression was only seen in 53% of pancreatic
cancer tissue. Though it was absent in normal pancreatic tissue,
C4.4A was also expressed in 40% of chronic pancreatitis. Thus, for
pancreatic adenocarcinoma, uPAR expression (Chen et al, 2007)
may be a more reliable parameter than C4.4A expression. In RCC,
the vast majority of which were clear cell carcinoma (Devitt et al,
2006), both C4.4A and uPAR (Bhuvarahamurthy et al, 2005)
expressions show low sensitivity. Still, C4.4A proved to be the
more sensitive marker.
Finally, the finding that C4.4A is released by cancer cells may
well become important for its potential use in colorectal cancer
diagnosis. Different forms of released C4.4A were detected. Part
of released C4.4A contains a GPI anchor and is likely vesicle-
associated. Vesicle shedding can occur in different normal cells
(Dainiak, 1991), but is strongly accelerated in cancer cells (Taylor
and Black, 1986). Similar to uPAR (Ploug et al, 1992; Wilhelm et al,
1999), the majority of released C4.4A has no GPI anchor, possibly
due to the activity of GPI-specific phospholipase D (Wilhelm et al,
1999). The supernatant of the ASML tumour line also contained a
C4.4A fragment, which corresponds in size to a cleavage product
generated by digestion of rrC4.4A. The size of the fragment is
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between the second and the third domain (Hansen et al, 2004).
Interestingly, soluble uPAR and uPAR fragments are present in the
blood of patients with different types of solid tumours, for example
non-small cell lung cancer, breast, colorectal, prostate and ovarian
cancer (Pappot et al, 1997; Stephens et al, 1997, 1999; Sier et al,
1998; Miyake et al, 1999), and are used as prognostic marker.
Moreover, vesicles shed in vivo by breast carcinoma are similar to
those shed in vitro by breast cancer cells and probably contribute
to tumour markers present in the circulation of cancer patients
(Dolo et al, 1995). Thus, it will be interesting to analyse the
presence of hC4.4A in the serum and ascitic fluid of cancer patients
and whether high enough amounts are present to allow for
detection by a sensitive ELISA.
Besides C4.4A expression, we were particularly interested in
galectin-3 expression, which we had described to be an interaction
partner for C4.4A (Paret et al, 2005). Galectin-3 is also expressed in
over 70% of colorectal primary tumours and liver metastasis.
Distinct to C4.4A, which is expressed exclusively by the epithelial
tumour cells, galectin-3 can also be expressed by stromal cells and
expression becomes upregulated in colitis ulcerosa tissue. Yet, the
differences between expression levels in inflamed and malignant
colorectal tissue remained significant. This is in line with several
reports (Byrd and Bresalier, 2004) on high-level expression of
galectin-3 in colorectal cancer. We did, however, not observe
significant differences in the intensity of expression between low-
and high-grade tumours and not in dependence on the disease-free
survival, although a prolonged disease-free survival was accom-
panied by a slight, statistically non-significant reduction in the
mean intensity of expression (1.43) as compared to metastasis
developing concomitantly with the primary tumour (mean
intensity: 1.73). Other studies revealed either similar results or
reported upregulation of galectin-3 expression during tumour
progression (Andre et al, 1999; Nakamura et al, 1999; Legendre
et al, 2003, Nagy et al, 2003; Endo et al, 2005). Particularly one of
the latter studies performed a highly sophisticated quantitation of
galectin-3 expression (Nagy et al, 2003). Taking into account that
we observed a slightly lower galectin-3 expression in metastasis
appearing after a prolonged disease-free survival, we would argue
that probably galectin-3 expression becomes upregulated during
tumour progression, but to a minor degree. Irrespective of this
open question, and in line with several reports, galectin-3 still
fulfils the criteria of a colorectal tumour marker with a sensitivity
of 0.79 and 0.83 and a specificity of 0.97 and 1.00 in primary and
metastatic tissue.
Our results suggest C4.4A as a candidate diagnostic marker for
colorectal cancer. The possibility of C4.4A as tumour marker in
body fluids remains to be explored. The advantage of C4.4A in
colorectal cancer diagnosis relies not only on the high frequency and
stability of expression, but particularly on the de novo expression of
this molecule in colorectal cancer tissues or the strongly upregulated
expression as for example in transitional cell cancer (Smith et al,
2001). In view of oligomerization and highly variable glycosylation
of C4.4A, establishing a monoclonal antibody by vaccination with
native, glycosylated C4.4A is desirable and may be mandatory for
low-level detection of C4.4A in body fluids.
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